Morpholine-3-Carboxamide EP4 Agonists for Local GI and Lung Action
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for gastrointestinal and pulmonary disorders, such as chronic constipation, inflammatory bowel disease, asthma, and chronic obstructive pulmonary disease, lack effective and safe EP4 receptor agonists that can provide complete symptomatic relief without cardiovascular systemic side effects.
Innovation Solution
Development of novel morpholine-3-carboxamide derivatives that act as selective EP4 receptor agonists, designed to promote intestinal fluid homeostasis and bronchodilation, with low gastrointestinal permeability to minimize systemic distribution and side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EP4 receptor agonists are used to treat gastrointestinal and pulmonary disorders, then therapeutic efficacy is improved, but cardiovascular systemic side effects occur due to high systemic distribution
Solution Approach 1:
The patent applies local quality by designing compounds with differential tissue distribution properties. The compounds achieve high concentration in gastrointestinal and pulmonary tissues where EP4 receptors are abundant, while maintaining low systemic circulation levels. This is accomplished through molecular structure optimization that enhances local tissue uptake and retention, thereby providing therapeutic efficacy at target sites while minimizing exposure to cardiovascular systems and reducing systemic side effects.
Solution Approach 2:
The patent employs the gastrointestinal and pulmonary tissues as intermediaries that selectively concentrate the EP4 agonist compounds. These tissues act as mediator compartments that receive and retain the compounds from systemic circulation, effectively decoupling the therapeutic action site from the systemic distribution pathway. This intermediary mechanism allows the compounds to exert pharmacological effects locally while limiting their passage through cardiovascular systems, thus reducing cardiovascular side effects.
2Quantity of substance
If systemic distribution is increased to achieve therapeutic levels, then drug concentration at target sites is improved, but cardiovascular side effects increase
Solution Approach 1:
The compounds are designed with molecular characteristics that confer selective tissue affinity for gastrointestinal and pulmonary epithelia. This local quality ensures that even at low systemic concentrations, the compounds achieve sufficient accumulation at target sites through enhanced permeability and retention mechanisms specific to these tissues. The structural features promote selective uptake via transporters or receptors present in high density in GI and pulmonary tissues, thereby achieving effective local concentrations without requiring high systemic exposure that would lead to cardiovascular side effects.
3Reliability
If selective EP4 agonist activity is enhanced, then therapeutic specificity is improved, but development complexity increases
Solution Approach 1:
The patent achieves selective EP4 agonist activity by systematically optimizing molecular parameters such as substituent groups on the core structure, stereochemistry, and physicochemical properties. Specific parameter ranges have been identified that correlate with EP4 selectivity, including particular substituent positions and types on the morpholine-3-carboxamide scaffold. By establishing structure-activity relationship (SAR) guidelines that define optimal parameter ranges, the patent reduces development complexity by providing clear design rules rather than requiring exhaustive screening of all possible structural variations.
Data Source
AI summary
The disclosures herein relate to novel compounds of formula I:and salts thereof, wherein X, Y, A, Ring B, R1, R2, R3, R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EP4 receptors.